Immunological evaluation of patients with Alzheimer's disease based on mitogen-stimulated cytokine productions and mitochondrial DNA indicators.
Alzheimer's disease
Mitogen
Peripheral blood mononuclear cell
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
08 03 2023
08 03 2023
Historique:
received:
04
09
2022
accepted:
27
02
2023
entrez:
8
3
2023
pubmed:
9
3
2023
medline:
11
3
2023
Statut:
epublish
Résumé
Based on its objective characteristics, laboratory markers have always been the research direction of clinical diagnosis and assessment of mental disorders including Alzheimer's disease. MTT Colorimetric Assay, ELISA, and quantitative PCR were used to investigate the responsiveness of peripheral blood mononuclear cells (PBMCs) to mitogen Lipopolysaccharides (LPS) and Phytohemagglutinin (PHA), PBMCs genomic methylation and hydroxymethylation levels, nuclear DNA and mitochondrial DNA damage, respiratory chain enzyme activities, and circulating cell-free mitochondrial DNA levels were detected in 90 patients with Alzheimer's disease. In the Alzheimer's disease group, LPS stimulated PBMCs viability, TNF-α secretion, PHA stimulated IL-10 secretion, genomic DNA methylation levels, circulating cell-free mitochondrial DNA copies, citrate synthase activity were reduced compared to the control; while the LPS stimulated PBMCs IL-1α secretion, PHA stimulated IL-1α and IFN-γ secretion, plasma IL-6 and TNF-α, mitochondrial DNA damages were increased compared to the control. The reactivity of peripheral blood mononuclear cells to mitogens, mitochondrial DNA integrity characteristics, and cell-free mitochondrial DNA copies may be used as candidate laboratory biomarkers to help clinical management of Alzheimer's disease.
Sections du résumé
BACKGROUND
Based on its objective characteristics, laboratory markers have always been the research direction of clinical diagnosis and assessment of mental disorders including Alzheimer's disease.
METHODS
MTT Colorimetric Assay, ELISA, and quantitative PCR were used to investigate the responsiveness of peripheral blood mononuclear cells (PBMCs) to mitogen Lipopolysaccharides (LPS) and Phytohemagglutinin (PHA), PBMCs genomic methylation and hydroxymethylation levels, nuclear DNA and mitochondrial DNA damage, respiratory chain enzyme activities, and circulating cell-free mitochondrial DNA levels were detected in 90 patients with Alzheimer's disease.
RESULTS
In the Alzheimer's disease group, LPS stimulated PBMCs viability, TNF-α secretion, PHA stimulated IL-10 secretion, genomic DNA methylation levels, circulating cell-free mitochondrial DNA copies, citrate synthase activity were reduced compared to the control; while the LPS stimulated PBMCs IL-1α secretion, PHA stimulated IL-1α and IFN-γ secretion, plasma IL-6 and TNF-α, mitochondrial DNA damages were increased compared to the control.
CONCLUSIONS
The reactivity of peripheral blood mononuclear cells to mitogens, mitochondrial DNA integrity characteristics, and cell-free mitochondrial DNA copies may be used as candidate laboratory biomarkers to help clinical management of Alzheimer's disease.
Identifiants
pubmed: 36890488
doi: 10.1186/s12888-023-04634-x
pii: 10.1186/s12888-023-04634-x
pmc: PMC9993804
doi:
Substances chimiques
Mitogens
0
Lipopolysaccharides
0
Tumor Necrosis Factor-alpha
0
Cytokines
0
DNA, Mitochondrial
0
Phytohemagglutinins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
145Informations de copyright
© 2023. The Author(s).
Références
J Appl Lab Med. 2020 Jan 1;5(1):194-208
pubmed: 31843944
Lancet Neurol. 2016 Jun;15(7):673-684
pubmed: 27068280
BMC Psychiatry. 2018 Sep 27;18(1):315
pubmed: 30261848
Braz J Med Biol Res. 2020;53(10):e9881
pubmed: 32813850
Int J Mol Sci. 2019 Nov 28;20(23):
pubmed: 31795299
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Methods Mol Biol. 2012;837:327-35
pubmed: 22215558
Ageing Res Rev. 2017 Nov;40:84-94
pubmed: 28941639
Curr Alzheimer Res. 2020;17(13):1186-1194
pubmed: 33583380
Ann Neurol. 2015 Dec;78(6):1000-4
pubmed: 26343811
Curr Protoc Toxicol. 2016 Feb 01;67:20.11.1-20.11.25
pubmed: 26828332
JAMA Ophthalmol. 2021 May 01;139(5):548-556
pubmed: 33764406
Alzheimers Dement. 2019 Aug;15(8):1071-1080
pubmed: 31422798
Front Aging Neurosci. 2021 Feb 12;13:585904
pubmed: 33643019
Acta Neuropathol Commun. 2017 Feb 2;5(1):13
pubmed: 28153046
Mol Psychiatry. 2021 Jul;26(7):3407-3418
pubmed: 33875800
Brain Behav Immun. 2014 Oct;41:251-60
pubmed: 24793756
JAMA Neurol. 2019 Jul 1;76(7):791-799
pubmed: 31009028
Neuroimmunomodulation. 2001;9(4):183-92
pubmed: 11847480
J Alzheimers Dis. 2017;57(1):37-43
pubmed: 28222525
Exp Gerontol. 2014 Jun;54:116-22
pubmed: 24440385
Immunol Rev. 2018 Jan;281(1):8-27
pubmed: 29247995
Brain Res Brain Res Rev. 2005 Jun;48(3):477-87
pubmed: 15914253
J Immunol. 2018 Jan 15;200(2):775-787
pubmed: 29222168
Front Immunol. 2019 May 09;10:1064
pubmed: 31143191
Antioxid Redox Signal. 2020 Jul 20;33(3):191-210
pubmed: 32143546
Methods Mol Biol. 2012;920:111-32
pubmed: 22941600
Neuropsychopharmacology. 2018 Jun;43(7):1557-1564
pubmed: 29453441
J Neurol Sci. 2017 May 15;376:242-254
pubmed: 28431620
Mol Neurodegener. 2018 Oct 3;13(1):51
pubmed: 30285785
Mol Neurodegener. 2020 Feb 18;15(1):10
pubmed: 32070373
Neurobiol Aging. 2013 Sep;34(9):2091-9
pubmed: 23582657
Cell Mol Neurobiol. 2000 Aug;20(4):433-50
pubmed: 10901265
Curr Alzheimer Res. 2008 Oct;5(5):457-68
pubmed: 18855587
BMC Psychiatry. 2018 Oct 12;18(1):330
pubmed: 30314474
Epigenetics Chromatin. 2016 Jun 29;9:26
pubmed: 27358654
Neurobiol Aging. 2004 Jan;25(1):105-10
pubmed: 14675736
Aging Cell. 2018 Aug;17(4):e12773
pubmed: 29745022
Alzheimers Dement. 2017 Jun;13(6):674-688
pubmed: 28089213
Biology (Basel). 2016 Oct 08;5(4):
pubmed: 27740596
Int J Mol Sci. 2020 Feb 28;21(5):
pubmed: 32121304
Nat Rev Immunol. 2010 Feb;10(2):89-102
pubmed: 20081871